Reports Benchmarking database Evaluating a benchmarking database and identifying cost reduction opportunities by diagnosis-related group SCOTT J. KNOER, RICHARD J. COULDRY, AND TANYA FOLKER Abstract: Pharmacy cost Index terms: Acyclovir; Ad- Am J Health-Syst Pharm. ospital administrators are under constant pres-Several widely used benchmarking databases have beensure to find new w
Australian people can buy antibiotics in Australia online here: http://buyantibioticsaustralia.com/ No prescription required and cheap price!
Nothing new (ethically) under the sun: policy & clinical implications of nanomedicineC MacDonald & B Williams-Jones BioéthiqueOnline 2012, 1/11 Nothing New (Ethically) Under the Sun: Policy & Clinical
Implications of Nanomedicine
ARTICLE (RÉVISION PAR LES PAIRS / PEER-REVIEWED)
Chris MacDonald1 & Bryn Wil iams-Jones2
Éditeurs/Editor: Charles Dupras, Jason Behrmann & Ali OkhowatÉvaluateurs externes/Peer-Reviewers: Todd Kuiken & Dominique McMahon Résumé
La recherche en nanotechnologie commence à recevoir Nanotechnology research is beginning to see une attention croissante dans les médias et la littérature de widespread coverage in the media and popular vulgarisation scientifique, mais les discussions sur les science literatures, but discussions of hopes and espoirs et les craintes concernant les nanotechnologies fears about nanotechnology have already become sont déjà polarisées par des visions utopiques et polarised into utopian and dystopian visions. More dystopiques. Par ailleurs, certaines discussions plus moderate discussions focus on the near-term modérées se concentrent sur les applications à court terme applications of nanotechnologies, and on potential des nanotechnologies, ainsi que sur leurs avantages et benefits and harms. However, in exploring the social désavantages potentiels. Cependant, en explorant les and ethical implications of nanotechnology (or implications sociales et éthiques des nanotechnologies (ou nanomedicine, the focus of this paper), important la nanomédecine, le but du présent document), lessons should be learned from experiences in other d'importantes leçons devraient être tirées des expériences fields. In particular, studies of the ethical, legal, and dans d'autres domaines. En particulier, les études sur les social issues (ELSI) of genetics research have enjeux éthiques, légaux et sociaux (ELSI) de la recherche successfully mapped out many of the issues (and en génétique ont réussi à cartographier un grand nombre social and political responses) that arise when new des questions (et des réponses sociales et politiques) qui technologies are deployed. It is our contention that, se posent lorsque de nouvelles technologies sont for the most part, the ethical and social issues déployées. Nous soutenons que, pour la plupart, les arising in nanomedicine are not altogether new, and questions éthiques et sociales qui se posent dans la thus do not require novel ethical principles or nanomédecine ne sont pas tout à fait nouvelles et ne frameworks, nor a massive investment in ‘NELSI’ nécessitent donc pas de nouveaux principes ou cadres research. Instead, what is needed is support for the éthiques, ni un investissement massif dans la recherche development of a culture of ethics amongst « NELSI ». Au lieu de cela, nous avons besoin d'un soutien scientists and clinicians, basic scientific and medical pour le développement d’une culture de l'éthique parmi les knowledge for bioethicists, and a social competency scientifiques et les cliniciens, des connaisances de base en for citizens to participate actively in debates about science et médicine pour les bioéthiciens et une the implications of new technologies in general. compétence sociale pour les citoyens pour qu’ils peut participer activement aux débats sur les répercussions des nouvelles technologies en général.
Nanotechnologies, éthique, financement de recherche, Nanotechnology, ethics, research funding, ELSI, C MacDonald & B Williams-Jones BioéthiqueOnline 2012, 1/11 Affiliations des auteurs / Author Affiliations
1 Law & Business Department, Ted Rogers School of Management, Ryerson University, Toronto, Canada
2 Programmes de bioéthique, Département de médecine sociale et préventive, Université de Montréal, Montreal,
Correspondance / Correspondence
Les auteurs tiennent à remercier Lori Sheremeta, Michael The authors would like to thank Lori Sheremeta, Burgess, Oonagh Corrigan et Stephen Modell pour leurs Michael Burgess, Oonagh Corrigan and Stephen commentaires utiles sur les différentes versions du Modell for their helpful commentary on various document, et les trois éditeurs et les deux examinateurs drafts of the paper, and the three editors and two externes pour leurs évaluations approfondies et peer-reviewers for their thorough and constructive constructives.
Conflicts of Interest
Bryn Williams-Jones est l’éditeur en chef de la revue, il a Bryn Williams-Jones is the Editor-in-chief of the co-écrit des articles avec Charles Dupras, a supervisé la Journal; he has co-authored with Charles Dupras, thèse de Jason Behrmann et supervise actuellement Ali supervised the PhD of Jason Behrmann, and Okhowat.
The last decade has been characterized by increasing hype about nanotechnology and
nanomedicine, often in the form of scientific and governmental exuberance about the potential
clinical (and economic) benefits. The ability to manipulate materials at the atomic or nanoscale –
whether they be physical (e.g., metals), chemical (e.g., polymers) or biological (e.g., DNA) in
nature – has enabled scientists to access special properties associated with quantum
mechanics (e.g., greater surface area, chemical reactivity) and develop new materials or
systems. But the very thing that makes nanotechnologies desirable can also limit our
understanding of how these properties may interact with other materials and systems at the
nano or macro scales. The enthusiam for “al things nano” has thus been matched by mounting
concern on the part of activists and social commentators about the safety of nanotech-derived
products and their impact on public health (e.g., pollutans or mutagens), and the potential social
and ethical issues (e.g., use for enhancement or military applications). Countless stories in the
print, television, and radio news have both enthused about the possibilities and lamented the
dangers of nanotechnology. Similarly, in the academic literature, health science research
published in journals as diverse as Biomedical Microdevices , Mycopathologia ,
Nanotechnology , and BMJ  has pointed to both the potential health benefits and risks
associated with nanomedicine. On the ethical, legal, and social side, we have seen articles
published in Technology Review  Columbia Science and Technology Law Review  and
Nanotechnology , and these have focused more on the particular challenges raised by
nanomedicine for individuals, institutions and society.
Much like the early debates about genetical y modified foods in the late 1990s , discussions about nanotechnology have also been characterised by utopian and dystopian visions of the future [9-11]. Between these extremes, discussion has centred on the impact that the anticipated breakthroughs in nanoscience and nanotechnology wil have upon existing chemical, material, biological and information sciences. In the case of biology and medicine, which are the focus of this paper, research points towards new means of circumventing problems faced by gene therapy and current methods of drug delivery, to name but two examples [12-14] But as is C MacDonald & B Williams-Jones BioéthiqueOnline 2012, 1/11 the case with many forms of scientific research and innovation, applications of nanomedicine wil not be without risks. Nanoparticles may target the wrong cells or interact negatively with the body’s proteins, enzymes, or organs; worse yet would be the uncontrolled replication of nanoparticles, potential y resulting in leukaemia-like phenomena similar to what has occurred with some viral-based gene therapy experiments [15,16]. Beyond the context of human health, nanotechnology innovations may raise concerns about the environment (e.g., risks of widespread contamination), regulatory issues (e.g., regulating in a context of significant scientific uncertainty about risk), privacy  and civil liberties (e.g., potential for low-cost and thus pervasive surveil ance), military applications (e.g., nanoscale weapons), etc. .
In seeking to understand the chal enges posed by developments in nanomedicine, we suggest that important lessons can and should be learned from research and policy on the ethical, legal, and social implications of genetics/genomics research, known as ELSI in the US and GE3LS (Genomics, ethics, environment, economic, legal issues) in Canada. As with nanotech, early developments in genetics (and then genomics) led to much scientific, policy and media hype, which was closely followed by public and academic concerns about health and safety issues, as wel as social and ethical challenges that needed attention (e.g., stigmatization, discrimination, designer babies). Two decades of ELSI research helped shape the development and implementation of genetic and genomic technologies, resulting in vigorous debate about and the production of a plethora of ethical frameworks and public policy on everything from informed consent regarding biobanking  to the direct-to-consumer marketing of genetic tests and other ‘personalised medicines’ . In line with other commentators , it is our contention that, for the most part, the socio-ethical and legal challenges or questions posed by nanomedicine are not altogether new or very different from those identified with genetics or genomics technologies. Such being the case, they do not necessarily require novel ethical frameworks nor a massive financial investment in ‘NELSI’ research because most of the ethical principles or tools needed to address the challenges posed by nanotechnology already exist, having been developed during three decades of ELSI research. What is needed, instead, is support for interdisciplinary collaborations between applied (nano)science and ELSI researchers to address problems related to nanotech as they arise , in order to develop a culture of ethics amongst scientists and clinicians, and ensure that bioethicists (and other humanities and social sciences scholars) have sufficient understanding of the basics of science and medicine. But it wil also be important to help the public develop a broader public or social competency – i.e., basic scientific knowledge and critical thinking skil s – so that citizens can be equiped to engage with debates about the implications of new technologies in general. Lessons from the World of Biotechnology and Genetic Engineering
Wel before the completion of the Human Genome Project in 2003, a substantial body of
academic and policy literature had developed, replete with stories of hope, hype, and fear about
the near term benefits and harms of genetics and genomics research. Within a decade, it was
promised, genetic testing and gene therapy would cure both rare and common diseases, and
pharmacogenomics (i.e., understanding the influence of genetic variation on drug response)
would revolutionise pharmaceutical development, drug delivery, and usher in a future of cost-
effective personalised medicine [23,24]. But these hopes have proven premature. Gene therapy
research, while showing some promise in the development of safe and effective delivery
mechanisms, has been marred by very public setbacks including the deaths of research
subjects , while in the case of pharmacogenomics, even putative exemplars of the
C MacDonald & B Williams-Jones BioéthiqueOnline 2012, 1/11 technology (e.g., Herceptin and Abacavir) have been of limited efficacy [26,27]. Cautious evaluations suggest that while there may eventually be practical applications of these technologies, they are unlikely to be ‘just around the corner’ . More vocal opponents argue that the public has been misled, and that the primary goals of massive government investments in the Human Genome Project and biotechnology had more to do with supporting ‘big science’ in pursuit of economic development and the creation of ‘knowledge-based economies’, than with improving human health . This is not to say that genetics research is a hopeless endeavour, only that the development of practical applications wil take longer, and be much less predictable, than was initial y promised .
It appears that with nanotechnology, history is to some extent repeating itself. The pattern of two-lane hype – glowing scientific optimism coupled with strident social criticism – is strikingly similar to the pattern so recently observed in relation to biotechnology . However, hype has its upside and its downside. While hype may be crucial for attracting initial research funding and sustaining scientific, government and public support, if overdone, hype can create unrealistic expectations that could lead to a loss of public trust [32-34]. However, empirical research is stil needed to see whether this loss of trust actual y occurs in practice, and with which technologies . Similarly, over-sensitivity to or disproportionate concern about particular technologies can lead to their implementation being significantly delayed or unduly constrained. A case in point was the focus on the human safety issues with GMO foods, which received considerable public attention despite a lack of scientific evidence to substantiate such risks. The misguided focus on human health and the related debate over the label ing of GM foods arguably shifted public attention away from more plausible concerns related to the environmental impact of GM crops . In a context where there is significant scientific uncertainty about the safety of a new innotvation, a precautionary approach is ful y justified and warranted to ensure the protection of public health and security. Our point, here, is that an overly hyped or polarised public debate about a class of technologies – such as GMOs, or for our purposes, nanotech – can lead to an entire sector being inappropriately “painted with the same brush”, thereby undermining the deployment of certain beneficial and safe innovations while also minimizing regulatory controls for those innovations that are clearly problematic.
The events of the last two decades – with ‘hyped’ biotech and genetic innovations being accompanied by substantial public and academic debate over associated ethical, legal and social implications – are, we suggest, being repeated in the case of nanotechnology. Putting aside the more extreme concerns about environmental disaster, expressed most dramatical y by Prince Charles’ fear of self-replicating nanorobots running amok and leading to a world overrun with “grey goo” , there are legitimate questions about the safety of some nanotech developments (including questions about pollution and toxicity) because of scientific uncertainy about how nanoparticules interact with biological systems (e.g., human lungs). But while the particular properties and behaviour of nanoparticles clearly require scientific study in order to determine when and how they might be toxic and thus in need of control (e.g., health and safety regulations), this does not mean that an entirely new field of environmental or health sciences is required with completely new tools or infrastructure. Like early reflections on the ethical, legal and social implications (ELSI) of genetic technologies, initial work on the ethics of nanotechnology seems to assume that ‘this stuff is radical y new,’ requiring a ‘new ethics’ because the existing ethical or conceptual tools are insufficient . The difference, however, is that nanotech ethics, or NELSI, is developing in a context where there is already a wel established field of research, i.e., ELSI. It is in important, then, for NELSI researchers to be modest in their cal s for support and attention to issues of legitimate concern in nanotech, and C MacDonald & B Williams-Jones BioéthiqueOnline 2012, 1/11 not to oversell their speciality as if it is an entirely new field, in need of completely new resources.
More Smoke than Fire?
Developments in genetics and biotechnology in the 1980s and 1990s led to substantial
international political, academic, and financial investment (US$100 mil ion invested by the US
government alone) in ELSI research . Faced with novel technologies and medical
procedures such as predictive testing for late-onset conditions, genetic testing for characteristics
and for variations between population groups, and embryonic procedures, it was deemed critical
to also consider the range of attendant social and ethical questions . Indeed, ELSI research
has gone a long way toward addressing many of these questions and supporting the
implementation of national and international policies and regulations to minimize and control
potential harms. For example, international and professional moratoria have been implemented
to protect against unjust discrimination in the use of genetic testing for health or life insurance
[20,41], and to prevent the genetic modification of germ-line tissues in face of the grave
misgivings concerning the genetic engineering of future generations . These moves
arguably resulted in large part from a wil ingness of researchers to engage in multi- or
interdisciplinary discussions, and so one of the real accomplishments of ELSI has been to bring
together diverse research communities. However, ELSI research has also been criticized for
being complacent about (if not complicit in) dominant social and political ideologies, and
insufficiently responsive to public concerns and the need for greater democratic involvement
[29,43]. Further, the focus of much ELSI research has been on the implications of a narrow
group of technologies (e.g., genetic tests, new reproductive technologies, stem cel research)
 and so has not given adequate consideration to the larger social and political contexts in
which these technologies manifest .
In light of both the strengths and weaknesses of ELSI, we should be cautious about calls for similar large-scale public investment in nanotechnology ethics, such as the US ‘NELSI’ programme, or as Mnyusiwalla, Daar and Singer propose for the Canadian context, ‘NE3LS’, the study of nanotechnology’s ethical, environmental, economic, legal, and social implications . According to these authors, “what is worrying…is that the serious study of NE3LS research lags far behind the science. Despite availability of research funds, NE3LS research has not yet been taken seriously and pursued on a large enough scale” [7, p. R9]. This concern, however, seems to play on the naïve view that science and technology develop in a vacuum, outside existing social, ethical and political discourses; and thus according to Mnyusiwal a et al, nanotechnology can be seen to ‘race ahead’ of the ethics because the ‘ethical issues’ are specific to the individual technology in question. Yet, as has been clearly demonstrated in the science and technology studies literature, technologies are invariably developed within and responsive to the larger social, political and cultural contexts, including socio-ethical debate [46-48]. We agree with Mnyusiwal a et al. that nanotechnologies present important social and ethical chal enges in need of critical study, such as the implications for privacy and civil liberties of the convergence between hitherto distinct technologies (telecommunication, computing, optics). Nonetheless, we maintain that many – if not most – of the social, ethical and legal concerns related to this technology, and in particularly those that relate to novel medicines, are similar to those arising with other new biomedical technologies, and for which we already have a set of tried and tested ethical tools, including principles and ethics frameworks. C MacDonald & B Williams-Jones BioéthiqueOnline 2012, 1/11 Ethics and Nanomedicine
Nanomedicine might be thought to be categorical y different from biotechnology because it is
inherently interconnected to the broader field of nanotechnology, a field that integrates or leads
to the convergence of domains as diverse as biology, material sciences, chemistry, particle
physics, public health and environmental science. In other words, the socio-ethical issues
associated with nanomedicine wil necessarily include considerations of public health,
environmental impact, and so on. However, even brief reflection on the issues posed by gene
therapies or other forms of genetic engineering demonstrate that biotechnologies can also have
socio-ethical and legal implications that extend beyond the strictly medical realm to concerns
about public health or environmental ethics (e.g., risk of epidemics through the introduction of
animal pathogens into the human population).
To be sure, nanomedicine offers many exciting new possibilities and poses numerous significant socio-ethical challenges. There wil , for example, be concerns related to constraints on experimentation on human research subjects that wil pose very real challenges for research ethics committees, health policy makers and regulators. As noted above, both benefits and harms may result from the introduction of nanoparticles into the human body. As is the case with all forms of technological innovation, some ‘skil ing-up’ to learn about the basic science and applications of nanomedicine wil be needed for proper/adequate oversight and associated regulatory initiatives, and there could plausibly be legal and safety considerations particular to nanomedicine. Yet, the simple fact that the technology is different does not mean that the ethical challenges raised by such research, or the principles that must govern the ethical or legal treatment of human research participants, wil differ. Whether the technology in question is a gene therapy, a genetic test, a pharmaceutical, or a nano-enhanced version of one of these, its testing on human research participants wil stil be subject to standard review procedures to ensure their free and informed consent, safety, and so on. . To begin with, fol owing pre-clinical animal testing that demonstrated potential effectiveness, research ethics review (based on principles of safety, efficacy, informed consent, and so on) would be required before proceeding to Phase I and Phase 2 clinical trials on humans. Similarly, in commercial contexts, the marketing of nanotechnologies wil raise issues familiar to those who study organisational, business, or technology ethics. Concerns may be raised here with regards to patentability, product safety, or the social responsibility of nanotech companies – concerns reminiscent of those studied in the context of the biotech and pharmaceutical industries . Thus novel scientific or clinical developments do not necessarily bring novel ethical considerations. While there may wel be chal enging applications of ethical precepts that warrant careful ethical consideration, new developments do not in general necessitate the articulation of entirely new ethical principles.
Keeping abreast of the latest clinical developments is a professional responsibility for medical practitioners. What wil the arrival of radical y new nanomedicines mean for them? We conclude this section with a note to the practicing physician, whose busy clinical life may seem like it is on the verge of being swamped by yet another technological revolution. It has been noted that practicing clinicians have faced substantial obstacles in incorporating the fruits of genetic science into their practices . The (apparently) imminent arrival of nanomedicine may seem like an impending catastrophic burden on the time that the average physician can allocate to continuing education. Will the coming of nanomedicine imply a vast range of new technical skil s and ethical issues for the practicing physician to master? The happy answer, here, is ‘no’. For the most part, nanomedicine will likely involve incremental (if sometimes striking) changes in the C MacDonald & B Williams-Jones BioéthiqueOnline 2012, 1/11 way clinical medicine is currently practiced. Nanomedicine may wel bring about new ways to deliver drugs, new ways to rebuild damaged tissues, and new ways to detect pathogens and toxins. But nanomedicine wil not fundatemal y change what it means to be a physician, nor wil it change the fundamental principles of medical ethics.
Do We Need ‘NELSI’?
In light of the above critique, we believe that the first grants handed out to researchers seeking
to study NELSI (such as two US$1 million grants from the US National Science Foundation,
given to two researchers ) have repeated the mistakes made by many of the granting
organisations that funded ELSI research. In both the biotech and the nanotech cases, granting
agencies – particularly those whose primary focus is on science – failed to see the differences
between research in, say, the development of nanomedicine itself, and research into the ethical
implications of nanomedicine. In the former case, giving out a few large grants to highly capable
teams may be an excel ent way to produce results. In the latter case, it is not. Providing
substantial dedicated funding for ethics projects about ‘big science’ (e.g., US ELSI or Canadian
GE3LS) has clearly stimulated collaboration, built capacity, led to more diverse research related
to the way the science and biotechnology are integrated into society, and revealed the
problematic nature of scientific and technological institutions [43,45]. Nevertheless, we suggest
that in the case of research on the socio-ethical and legal implications of nanomedicine, what is
needed now is more funding to support existing (and to stimulate new) multidisciplinary and
interdisciplinary collaborative networks, alongside a broad range of smaller research projects
that encourage diverse and divergent perspectives and socio-ethical analyses . Funding
agencies ought not to place all of their analytical eggs into only a few baskets; instead, they
should support a wide diversity of researchers from the bioethics community to help map actual
and emerging NELSI in order that scientists, regulators and civil society can be equipped to
prevent the most problematic situations, and manage appropriately the introduction of beneficial
The rapid advance of new technologies of all kinds, and their rapid integration into clinical practice, clearly demonstrate the need for detailed social science and empirical bioethics research to investigate the particular social and technical details and contexts in which nanotechnology wil develop . But this does not imply the need for multi-mil ion dol ar research projects focusing on ethical nuances of particular technologies. To return then to Mnyusiwal a et al.’s cal for increased research and funding of NE3LS or NELSI, if they are understood (which we believe they ought to be) as calling not for a repeat of ‘big team’ ethics research into particular technologies, but instead as calling for support of a broader multidisciplinary discussion and capacity development, then we would agree with this aspect of their proposal. We would go a step further, however, and argue for funding directed towards the development of a broad social competency to deal with the ethical implications of new technologies in general. Funding programs exclusive to one technology or discipline, such as research premised on the notion of ‘genetic exceptionalism,’ would not yield comprehensive approaches to technology adaptation nor win broad support. In this regard, we make the fol owing suggestions: 1. Ethics should be an integral part of the education and mentoring of young scientists and clinicians. We here join the chorus of scholars and educators calling for the creation of a culture of ethics in science . Exactly how to create such a culture is a difficult – and researchable – question . It is also an excel ent question for funding by research C MacDonald & B Williams-Jones BioéthiqueOnline 2012, 1/11 councils interested in dealing effectively with the ethical implications of novel technologies of al kinds.
2. Our universities and public regulatory bodies need to do more to produce social scientists, philosophers, legal scholars, and policy-developers with a reasonable degree of understanding of science and medicine. Most of those currently engaged in examining the ELSI of biotechnologies, for example, had to learn late in life the science needed to understand the intricacies of genetic testing or stem cell research. Granting councils should therefore make resources and opportunities available for teams dedicated to developing cross-disciplinary competency, and to research projects dedicated to determining suitable curricula for producing scientifically savvy humanists and social scientists.
3. We need to do better at educating and engaging the general public on issues related to the social and ethical implications of new technologies. How to do this is of course not an easy question, and the need for dialogue should not be mistaken for a need for persuasion [55,56]. Some wil inevitably argue that the public’s deficit in terms of their understanding of science is so severe that our proposal implies a Herculean effort. This, we think, is a mistaken supposition. The average university undergraduate can be taught, in just minutes, enough about the basic science of somatic cell nuclear transfer, for example, to allow him or her to arrive at informed opinions on the various arguments offered in relation to the ethics of human cloning. If the public is to be engaged, what we should be striving for is not perfect public understanding in pursuit of total public participation, but rather sufficient public understanding in pursuit of meaningful public participation. This, too, is a researchable – and fundable – chal enge .
New, paradigm-bending technologies such as nanomedicine always present choices, and there
are clearly important social and ethical concerns raised by developments in nanotechnology. We
must take seriously the utopian/dystopian extremes because they set out the poles of the
debate, while also reflecting to some extent the concerns of the general public. Detailed ethical
analysis and social scientific critique wil be needed of the near-term practical applications of
nanotechnology . But it is our contention that, in most cases, it is the specific context or
details of the technology in question that differ (genetics, pharmaceuticals, nanotech), and not
the substance of the ethical implications inherent with biomedical innovation . For whether
the particular technology at hand is biotechnology or nanotechnology or information technology,
the over-arching questions are largely the same . Who wil be harmed, and who wil benefit?
Are the gains and losses likely to be shared equitably? How wil this new technology affect us as
people, and as a community? Addressing these questions wil help to indicate whether any
policy improvisation or new regulations are cal ed for.
We need a combination of ethically thoughtful scientists and policy-developers, scientifical y savvy academics in the social sciences and humanities, and a public with sufficient scientific literacy to participate, in an informed way, in what is sure to be an on-going set of debates about the role of science and technology in our individual and collective lives. Caution – but not cynicism – is required in discussions about the hopes for and fears of nanotechnology, and this should be part of a more robust social competency for grappling with the social and ethical issues related to novel technologies of al kinds.
C MacDonald & B Williams-Jones BioéthiqueOnline 2012, 1/11 List of References
1. Bergey, E.J., Levy, L., Wang, P., Krebs, L.J., Lal, M., Kim, K.S., Pakatchi, S., Liebow, C. &
Prasad, P.N. 2002. "DC magnetic field induced magnetocytolysis of cancer cel s targeted by LH-RH magnetic nanoparticles in vitro" Biomedical Microdevices 4: 293-299 2. Myc, A., Vanhecke, T., Landers, J.J., Hamouda, T. & Baker Jr., J.R. 2001. "The fungicidal activity of novel nanoemulsion (X8W 60 PC) against clinical y important yeast and filamentous fungi" Mycopathologia 155(4): 195-201 3. Chasiotis, I., Fil more, H.L. & Gil ies, G.T. 2003. "Atomic force microscopy measurement of cytostructural elements involved in the nanodynamics of tumour cel invasion" Nanotechnology 14(5): 557-561 4. Borriel o, S.P. 1999. "Near patient microbiological tests" British Medical Journal 319(7205): 5. Rotman, D. 2003. MIT Technology Review April 6. Mil er, J. 2003. Columbia Science and Technology Law Review IV: 1-35 7. Mnyusiwal a, A., Daar, A.S. & Singer, P.A. 2003. "‘Mind the gap’: Science and ethics in nanotechnology" Nanotechnology 14(3): R9-R13 8. Mil stone, E. 2000. "Analysing biotechnology's traumas" New Genetics & Society 19(2): 117- 9. Drexler, K.E. 1986. Engines of Creation: The Coming Era of Nanotechnology. (New York: (London: Greenpeace Environmental Trust).
12. Emerich, D.F. & Thanos, C.G. 2003. "Nanotechnology and medicine" Expert Opinion on 13. Vijayanathan, V., Thomas, T. & Thomas, T.J. 2002. "DNA nanoparticles and development of DNA delivery vehicles for gene therapy" Biochemistry 41(48): 14085-14094 14. Miyazaki, S., Takahashi, A., Kubo, W., Bachynsky, J. & Loebenberg, R. 2003. Journal of Pharmacy and Pharmaceutical Sciences 6(2): 238-45 15. Stern, S.T. & McNeil, S.E. 2008. "Nanotechnology Safety Concerns Revisited" Toxicological C MacDonald & B Williams-Jones BioéthiqueOnline 2012, 1/11 16. Singh, S. & Nalwa, H.S. 2007. "Nanotechnology and Health Safety Toxicity and Risk Assessments of Nanostructured Materials on Human Health" Journal of Nanoscience and Nanotechnology 7(9): 3048-3070 17. MacDonald, C. 2004. "Nanotechnology, privacy and shifting social conventions: Privacy and nanotechnology" Health Law Review 12(3): 37-40 18. Stang, C. & Sheremeta, L. 2006. "Nanotechnology – A Lot of Hype Over Almost Nothing?" 19. Master, Z., Nelson, E., Murdoch, B. & Caulfield, T. 2012. "Biobanks, consent and claims of consensus" Nature Methods 9(9): 885-888 20. Nuffield Council on Bioethics. 2010.
(London: Nuffield Coucil on Bioethics).
21. Kuiken, T. 2011. "Nanomedicine and ethics: is there anything new or unique?" Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 3(2): 111-118.
22. Viseu, A. & Maguire, H. 2012. "Integrating and Enacting ‘Social and Ethical Issues’ in Nanotechnology Practices" NanoEthics 6(3): 195-209.
23. Wil iams-Jones, B. & Corrigan, O.P. 2003. "Rhetoric and hype: Where's the "ethics" in pharmacogenomics?" American Journal of Pharmacogenomics 3(6): 375-383 24. Hedgecoe, A. & Martin, P. 2003. "The drugs don't work: Expectations and the shaping of pharmacogenetics" Social Studies of Science 33(3): 327-364 25. St George, J.A. 2003. "Gene therapy progress and prospects: adenoviral vectors" Gene 26. Haseltine, W.A. 1998. "Not quite pharmacogenetics" Nature Biotechnology 16(13): 1295 27. Lindpaintner, K. 2002. "The importance of being modest: Reflections on the pharmacogenetics of abacavir" Pharmacogenomics 3(6): 835-838 28. Freund, C.L. & Wilfond, B.S. 2002. "Emerging ethical issues in pharmacogenomics: From research to clinical practice" American Journal of Pharmacogenomics 2(4): 273-281 29. Huijer, M. 2003. "Reconsidering Democracy: History of the Human Genome Project" Science Communication 24(4): 479-502 30. Evans, J.P., Meslin, E.M., Marteau, T.M. & Caulfield, T. 2011. "Deflating the Genomic Bubble" Science 331(6019): 861-862 31. Wil iams-Jones, B. 2004. "A spoonful of trust helps the nanotech go down" Health Law C MacDonald & B Williams-Jones BioéthiqueOnline 2012, 1/11 32. Caulfield, T.A. 2000. "Underwhelmed: Hyperbole, regulatory policy, and the genetic revolution" McGil Law Journal 45(2): 437-460 33. Brown, N. 2003. "Hope against hype – Accountability in biopasts, presents and futures" 34. Nightingale, P. & Martin, P. 2004. "The myth of the biotech revolution" Trends in 35. Master, Z. & Resnik, D.B. 2011. "Hype and Public Trust in Science" Science and Engineering Ethics, Published Online First: November 2 2011.
36. MacDonald, C. & Whel ams, M. 2007. "Corporate decisions about labeling genetical y modified foods" Journal of Business Ethics 75(2): 181-189 38. Litton, P. 2007. "'Nanoethic'”?: What's New?" Hastings Center Report 37(1): 22-25 39. ELSI Research Planning and Evaluation Group. 2000. Final Report: A Review and Analysis of the Ethical, Legal, and Social Implications (ELSI) Research Programs at the National Institutes of Health and the Department of Energy (Washington, D.C.: NHGRI).
40. Watson, J.D. 1992. "A personal view of the project" In The Code of Codes: Scientific and Social Issues in the Human Genome Project, edited by D.J. Kevles & L. Hood. (Cambridge, MA: Harvard University Press), p. 164-173.
41. Human Genetics Commission. 2003. Genes direct: Ensuring the effective oversight of genetic tests supplied directly to the public (London: Human Genetics Commission, Department of Health) 42. Berg, P. 2008. "Meetings that changed the world: Asilomar 1975: DNA modification secured" 43. McCain, L. 2002. "Informing technology policy decisions: the US Human Genome Project’s ethical, legal, and social implications programs as a critical case" Technology in Society 24: 111–132 44. Lehrman, S. 2000. The Gene Letter 1(7): 1-3 45. Evans, J.H. 2002. Playing God? Human Genetic Engineering and the Rationalization of Public Bioethical Debate. (Chicago: University of Chicago Press) 46. MacKenzie, D. & Wajcman, J., eds. 1999. The Social Shaping of Technology. 2nd ed. (Philadelphia: Open University Press).
47. Nowotny, H., Scott, P. & Gibbons, M. 2001. Re-Thinking Science: Knowledge and the Public in an Age of Uncertainty. (Cambridge: Polity Press) C MacDonald & B Williams-Jones BioéthiqueOnline 2012, 1/11 48. Webster, A. 1991. Science, Technology and Society, Sociology for a Changing World. (New 49. MacDonald, C. 2004. The Scientist 18(3): 8 50. Caulfield, T.A. 1999. "Gene testing in the biotech century: Are physicians ready? [Editorial]" Canadian Medical Association Journal 161(9): 1122-1124 Office of Legislative and Public Affairs 52. Wood, S., Jones, R. & Geldart, A. 2003. The Social and Economic Chal enges of Nanotechnology (Swindon: UK Economic and Social Research Council) 53. McDonald, M. 2001. "Canadian governance of health research involving human subjects: is anybody minding the store" Health Law Journal 9(1): 1-21 54. Master, Z., McDonald, M. & Wil iams-Jones, B. 2012. "Promoting Research on Research Integrity in Canada" Accountability in Research 19(1): 47-52 55. Kerr, A., Cunningham-Burley, S. & Amos, A. 1998. "The new genetics and health: Mobilizing lay expertise" Public Understanding of Science 7(1): 41-60 56. Petersen, A., Anderson, A., Al an, S. & Wilkinson, C. 2009. "Opening the black box: scientists’ views on the role of the news media in the nanotechnology debate" Public Understanding of Science 18(5): 512-530 57. Burgess, M.M. 2003. "Public consultation in ethics: An experiment in representative ethics" Journal of Bioethical Inquiry 1(1): 4-13 58. Mehta, M.D. 2004. "From Biotechnology to Nanotechnology: What Can We Learn from Earlier Technologies?" Bul etin of Science, Technology & Society 24(1): 34-39
WWW.XYNG.ORG.UK; e-mail: email@example.com ; 078307 88822 XYNG - Fuel 4 Life This product is a blend of all-natural ingredients designed to help you achieve your weight loss goals and feel incredible while you do it. A powerful blend of herbal ingredients, vitamins and minerals that control your appetite, increase your energy and create a euphoric feeling of excitement and positive mental